Buy, hold or sell: ResMed, Origin Energy and Reece shares
AI Market Summary
ResMed's Q1 beat - revenue up 6% to US$1.4bn, EPS up 23% to US$2.92, net profit 9% above consensus, over US$1bn returned via buybacks and dividends, and reiterated 5-7% full-year revenue guidance - underpins Macquarie's outperform and US$47.50 target. Read-through is confined to medtech and healthcare-equipment sentiment; index-level impact is marginal, though it supports the resilient elective-healthcare spending narrative.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+1.19%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
ResMed's first-quarter revenue rose 6% to US$1.4 billion. Earnings per share increased 23%. The company reiterated its full-year revenue growth guidance of 5% to 7%.
